Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Claims

Claim checks

Common statements get a verdict and supporting sources.

VERDICT Overstated

“Ibogaine cures addiction.”

Evidence suggests possible effects on withdrawal, craving, and relapse for some people, but cure language outruns the evidence and hides risk.

VERDICT False

“The FDA allowed Noribogaine, so it is approved.”

FDA allowed an early phase study to proceed. That is not approval and does not establish safety or effectiveness.

VERDICT False

“Natural means safe.”

Iboga and Ibogaine can be natural and still carry serious cardiac and interaction risks.

VERDICT Weak evidence

“A clinic success rate proves efficacy.”

Outcome claims need denominator, follow-up window, definition of success, adverse-event reporting, conflicts, and independent review.